Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Operating Leases (2022 - 2025)

Historic Operating Leases for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $2.1 million.

  • Phathom Pharmaceuticals' Operating Leases changed N/A to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $462000.0 for FY2023, which is 5792.35% down from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Operating Leases stood at $2.1 million.
  • In the past 5 years, Phathom Pharmaceuticals' Operating Leases ranged from a high of $2.1 million in Q3 2025 and a low of $133000.0 during Q2 2024
  • In the last 4 years, Phathom Pharmaceuticals' Operating Leases had a median value of $867000.0 in 2023 and averaged $898416.7.
  • Its Operating Leases has fluctuated over the past 5 years, first plummeted by 8314.32% in 2024, then soared by 34285.71% in 2025.
  • Phathom Pharmaceuticals' Operating Leases (Quarter) stood at $1.1 million in 2022, then crashed by 57.92% to $462000.0 in 2023, then tumbled by 71.21% to $133000.0 in 2024, then soared by 1496.24% to $2.1 million in 2025.
  • Its Operating Leases stands at $2.1 million for Q3 2025, versus $589000.0 for Q2 2025 and $133000.0 for Q2 2024.